Suggested Remit: To appraise the clinical and cost effectiveness of zanubrutinib within its marketing authorisation for treating Waldenström’s macroglobulinaemia.
|
Status
|
In progress
|
|
Decision
|
Selected
|
| Process |
STA 2018
|
| ID number |
1427
|
Provisional Schedule
| Expected publication |
19 October 2022 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors |
BeiGene |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Blood Cancer UK |
| |
Lymphoma Action |
| |
WMUK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Janssen-Cilag |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
09 August 2022
|
Committee meeting: 2 |
|
29 June 2022 - 20 July 2022
|
Draft guidance: 2 |
|
07 June 2022
|
Committee meeting: 2 |
|
06 May 2022 - 26 May 2022
|
Draft guidance |
|
12 April 2022
|
Committee meeting: 1 |
|
09 December 2021
|
The appraisal timelines have now been updated and the first appraisal committee meeting is now scheduled to take place on 12 April 2022. |
|
24 June 2021
|
NICE have taken the decision to pause this appraisal due to operational reasons, timelines are currently to be confirmed. |
|
15 February 2021
|
The timelines for this appraisal have been revised and the first appraisal committee meeting is now scheduled to take place on 7 September 2021. This is to allow the company to address the decision problem in the final scope in its submission. |
|
27 October 2020
|
Invitation to participate |
|
23 July 2020 - 20 August 2020
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
31 July 2017
|
In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual